Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Viremia residual e indetectabilidade

Os resultados de sub-análises de estudos randomizados controlados, que comparam a eficácia de regimes de terapia dupla, contendo dolutegravir, com regimes de terapia tripla.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/Portal_Medico/20181106_highlights_GLASGOW2018_HIV_%20Viremia%20residual_e_indetectabilidade_BR-HIVP-0117-18.mp4

   

  • Referências

    *Os estudos SWORD-1 e SWORD-2 avaliaram DTG + RPV (n= 513) versus terapia atual com 3 fármacos (n=511)

    **Na subanálise dos estudos SWORD-1 e SWORD-2 para identificação de blips, os grupos avaliados foram: switch precoce para DTG + RPV (n=513); switch tardio para DTG + RPV (n=477); terapia atual com 3 fármacos (n=511).

    1. LLIBRE, JM. et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet; 391(10123):839-849, 2018.

    2. WANG, R. et al. Comparison of viral replication for two-drug (DTG+RPV) versus three-drug current antiretroviral regimen (CAR) in the SWORD-1 and SWORD-2 studies. P313. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    3. UNDERWOOD, M. et al. Comparison of viral replication below 50 copies/mL for two-drug (DTG+RPV) versus three-drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies. P311. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    4. LI, J. et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. O145. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    5. TAIWO, BO. et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis; 66(11):1794-1797, 2018.

    6. LI, J. et al. Effect of DTG + 3TC switch on residual viremia. In: HIV Drug Therapy, Glasgow 2018. Disponível em: <http://www.natap.org/2018/GLASGOW/GLASGOW_13.htm>. Acesso em: 05 nov. 2018.

    7. GILLMAN, J. et al. Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy. O213. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    8. GILLMAN, J. et al. Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy. In: HIV Drug Therapy, Glasgow 2018. Disponível em: <http://www.natap.org/2018/GLASGOW/GLASGOW_16.htm>. Acesso em: 05 nov. 2018. 

    9. STELLBRINK, HJ. et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS; 27(11):1771-8, 2013.

    10. WALMSLEY, S. et al. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr; 70:515–519, 2015.